European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 27-31, January 2008

Effectiveness of eprosartan in diabetic hypertensive patients

  • N.R. Robles

      Affiliations

    • Department of Nephrology, Hospital Infanta Cristina, Badajoz, Spain
    • Corresponding Author InformationCorresponding author: Service of Nephrology Hospital Infanta Cristina Carretera de Portugal s/n E-06080 Badajoz, Spain. Tel.: +34 942 218100; fax: +34 924 218117.
    • ,
  • B. Martín-Águeda

      Affiliations

    • Medical Department Juste S.A.Q.F., Madrid, Spain
    • ,
  • F. López-Muñoz

      Affiliations

    • Department of Pharmacology, University of Alcalá, Madrid, Spain
    • ,
  • C. Álamo

      Affiliations

    • Department of Pharmacology, University of Alcalá, Madrid, Spain
    • ,
  • on behalf of the investigators of the ESTEPP study

Received 1 November 2006; received in revised form 31 March 2007; accepted 20 April 2007. published online 18 October 2007.

Abstract 

Background

The aim of this study was to compare the effectiveness and safety of eprosartan in reducing blood pressure in a group of diabetic patients and a group of non-diabetic patients in a primary care setting.

Methods

The ESTEPP (Efficacy and Safety of Treatment with Eprosartan on Pulse Pressure) study was open, prospective, multi-centered, and observational. It compared the results obtained from diabetic (n=114, age 65.0±10.7 years, 46.4% men and 53.6% women) and non-diabetic patients (n=435, age 62.5±11.4 years, 45.8% men and 54.2% women). All patients had mild to moderate hypertension (VI JNC) and were treated with eprosartan (600 mg) once daily. They had four follow-up visits in 16 weeks. At each visit, blood pressure (using a semiautomatic OMRON 705CP device), adverse effects, and treatment compliance were checked.

Results

Blood pressure decreased significantly (P<0.0001) in both diabetic and non-diabetic patients: SBP (25.9 mmHg vs. 26 mmHg), DBP (12.5 mmHg vs. 13.2 mmHg), MAP (16.9 mmHg vs. 17.5 mmHg), and pulse pressure (13.4 mmHg vs. 12.8 mmHg). Pulse pressure/MAP ratio showed a significant reduction in diabetics (baseline: 64±15%; final: 61±12%) and non-diabetics (baseline: 61±14%; final: 58±11%). The adverse effect rate was 7% in diabetic patients and 2.8% in non-diabetics. Treatment compliance did not differ between the groups (diabetics 98.0%, non-diabetics 92.2%).

Conclusions

Eprosartan seems to be effective in reducing SBP, DBP, and pulse pressure in hypertensive subjects and to the same extent in both diabetic and non-diabetic patients.

Keywords: Hypertension, Eprosartan, Diabetes mellitus

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0953-6205(07)00246-4

doi:10.1016/j.ejim.2007.04.022

European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 27-31, January 2008

Article Tools

* Image Usage & Resolution